Genotec DX and Midwest Toxicology: A Laboratory in Name Only
In the Genotec DX and Midwest Toxicology fraud case, a Missouri physician-owner admitted in his guilty plea that fraudulent laboratory claims cost Medicare, Medicaid and other health care insurers more than $3.8 million. The scheme connected a medical practice, hidden laboratory ownership and tests performed elsewhere to claims that concealed who had done the work. Midwest went further: it billed as a laboratory despite having no testing equipment, staff or supplies. For an insider who knows the bench and the billing system, the gap between what the lab could do and what the claims said is the story.
The Justice Department’s November 15, 2022 announcement of the physician’s guilty plea describes how the businesses fit together. Advanced Geriatric Management operated a laboratory. The physician and a business partner opened Genotec in the same building, then incorporated Midwest Toxicology Group the following year. The claims presented laboratory identities that concealed both the ownership relationship and who actually performed the tests.
Shared Equipment, Separate Laboratory Representations
The physician’s plea agreement described false statements used to obtain Genotec’s certification under the Clinical Laboratory Improvement Amendments. The business partner and Advanced Geriatric Management staff told the certification authorities that Genotec and the practice’s laboratory operated separately. They shared a part-time employee, a medical director and the same testing equipment.
Advanced Geriatric Management received its CLIA certification in 2014. Genotec opened that year and would bill insurers as a separate out-of-network laboratory. According to the plea account, Genotec needed its own certification before it could perform clinical laboratory testing. The false description of separate operations helped obtain the certificate that made that presentation possible.
Those details put the certification paperwork beside the working laboratory. The shared employee and medical director connected names that the application presented as separate. For a laboratory director or bench employee, the useful comparison is concrete: who staffed the bench, who directed the work and what the application said about those same people.
Hidden Ownership Behind the Referrals
The same physician whose practice supplied specimens had a financial interest in Genotec that insurers did not see. In his plea, he admitted choosing to remain deliberately ignorant of the concealment of that interest from private insurers, Medicare and Medicaid.
That concealment mattered at the point of referral. The plea account says insurers did not know that the physician and Advanced Geriatric Management employees were sending patients for urine testing to a laboratory in which he had a financial interest. A claim from a separate laboratory left out the relationship that helped bring the specimen there.
The ordering network extended beyond Advanced Geriatric Management. The physician admitted that he and providers at Millennium Psychiatric Associates, Sleep Consultants and Rest Easy of St. Louis ordered tests that entered the same outside-testing arrangement. His business partner ran Rest Easy. The practice names describe where the orders came from. The laboratory names describe where the claims appeared to come from. The ownership relationship connected the two.
For a practice manager, the useful knowledge may be who directed those referrals. For an enrollment or billing employee, it may be what the insurer was told about ownership. We look at those accounts together because the plea describes a financial relationship hidden across them.
Who Performed the Urine Drug Tests?
Outside reference laboratories performed the more sophisticated testing, according to the physician’s plea. Advanced Geriatric Management’s equipment detected the presence of drugs. The specimens sent out for further testing produced measurements of drug quantities.
According to the physician’s plea, Advanced Geriatric Management or Genotec paid the reference laboratories about $125 for a test, then billed insurers significantly more. They concealed that neither Advanced Geriatric Management nor Genotec had performed that testing. The physician’s plea said Medicare, Medicaid and many private insurers would not have paid those pass-through billing claims had they known.
The reference laboratory’s work produced the result. The intermediary’s claim took credit for it. A reference-lab invoice and the corresponding claim can therefore tell sharply different stories about the same specimen.
Midwest Borrowed the Certification Number
Midwest Toxicology Group submitted claims using Genotec’s CLIA number even though Midwest had no certification of its own. The physician’s plea described Midwest, incorporated in 2015, as a laboratory in name only. It lacked the equipment, staff and supplies needed to test human specimens.
The physician admitted knowing Midwest had no operating laboratory behind it while causing it to bill for clinical tests. He also admitted that he knew, or chose not to know, that his business partner used Genotec’s certification number on Midwest’s reimbursement claims. According to the plea, this deceived insurers into believing Midwest had performed the testing.
That was a different misrepresentation from the one used to obtain Genotec’s certificate. Genotec’s application described separate operations where equipment and personnel were shared. Midwest’s claims borrowed the resulting certification number to give a laboratory with no testing operation the appearance of one. The number on the claim connected the two businesses even when their names did not.
One Specimen, Two Claims
The same specimen billed by two labs was another part of the physician’s plea account. Genotec and Midwest frequently split-billed: each submitted a claim for testing the same specimen from the same person on the same date of service.
The earlier September 24, 2020 indictment announcement charged that the false claims covered genetic tests as well as quantitative urine drug tests. It also described how the operators unbundled tests that should have been billed together, submitted them separately and received $30,000 to $50,000 for a single urine drug test. The indictment alleged that claims for the same patient and service date went in on different days with different billing codes to avoid detection.
The plea’s split-billing account concerns two laboratory names claiming payment for the same specimen. The indictment’s unbundling allegation concerns tests broken into separate billable pieces. Those are distinct ways of multiplying claims around the same testing event.
The indictment announcement said that UFCW Local #655 paid Genotec $1,086,450 for urine drug tests for just seven members between January and October 2015. The union also paid Midwest $150,596.
What a Laboratory Insider Can See
This case puts particular weight on the certification application, the reference-laboratory invoice and the claim carrying the laboratory’s identity. Together, they connect the operation described to regulators, the work purchased elsewhere and the service presented to the payer. We use an insider’s knowledge of those records to explain how a real test became a misleading claim.
A bench employee may recognize the testing capacity. A practice employee may know the referral relationship. A biller may see the certification number and the repeated specimen. Each view can explain a part of the transaction that the claim alone conceals.
You Know Which Laboratory Did the Work
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. If you know whose equipment produced the result, whose number went on the claim or who benefited from the referrals, tell our whistleblower experts what you saw. We build your laboratory fraud case around those connections, bring in healthcare fraud whistleblower lawyers who understand laboratory billing, and stay with you through the pursuit of a recovery.
